<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563979</url>
  </required_header>
  <id_info>
    <org_study_id>KEK 152/07</org_study_id>
    <nct_id>NCT00563979</nct_id>
  </id_info>
  <brief_title>Enhancement of Macular Pigment Density by Oral Lutein Supplementation</brief_title>
  <acronym>EMPOLS</acronym>
  <official_title>Enhancement of Macular Pigment Density by Oral Lutein Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of EMPOLS is an increase in macular pigment density (MPD) and contrast
      sensitivity (CS) after six months supplementation of oral non-compound ester Lutein 10 mg
      daily, contained in VitaluxPlus®.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of EMPOLS is an increase in macular pigment density (MPD) and contrast
      sensitivity (CS) after six months supplementation of oral non-compound ester Lutein 10 mg
      daily, contained in VitaluxPlus®. Primary variable for a significant change will be 10%
      increase compared to baseline MPD.

      The measurement will be carried out by means of a modified confocal scanning laser
      ophthalmoscope (HRA) recording autofluorescence images at 488 nm and 514 nm 6. MPD is
      determined on MPD maps within 0.5 degrees around the center of the fovea. All MPD
      measurements and photographs will by performed by the Bern Photographic Reading Center
      (BPRC). Complete examination of study patients comprises testing of standardized visual
      acuity (ETDRS-VA), visual contrast sensitivity (CS), biomicroscopy, fundus photography, and a
      blood sample. Participating patients also have to fill out a food frequency questionnaire
      (FFQ-Bern) allowing for correction of additional lutein intake by regular diet. Moreover
      possible confounding factors e.g. as sunlight exposure or smoking habits will be assessed.
      Secondary objective of EMPOLS is the effect of oral non-compound ester lutein supplementation
      on CS and ETDRS-VA during one year. The variable for a significant change in ETDRS-VA is loss
      or gain of 7 letters on the ETDRS chart, for a change in CS: loss or gain of at least four
      letters on the Pelli-Robson CS Chart. Additionally, serum carotenoid levels of lutein will be
      determined by high performance liquid chromatography (HPLC) for each visit 1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Macular pigment density</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>contrast sensitivity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Age-Related Maculopathies</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VitaluxPlus®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omega 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VitaluxPlus®</intervention_name>
    <description>1 tablet daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega 3</intervention_name>
    <description>1 tablet daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age related maculopathy

        Exclusion Criteria:

          -  exudative age related degeneration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian Wolf, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Bern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ute Wolf-Schnurrbusch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Augenheilkunde, University Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2007</study_first_submitted>
  <study_first_submitted_qc>November 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2007</study_first_posted>
  <last_update_submitted>June 10, 2015</last_update_submitted>
  <last_update_submitted_qc>June 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Inselspital, Berne</investigator_affiliation>
    <investigator_full_name>Sebastian Wolf</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>age related macular degeneration</keyword>
  <keyword>supplementation</keyword>
  <keyword>macular pigment</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

